OBJECTIVE： To observe clinical efficacy and safety of linezolid， teicoplanin and vancomycin in the treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus （MRSA）. METHODS： 120 patients diagnosed as hospital-acquired MRSA pneumonia were divided into linezolid group， teicoplanin group and vancomycin group according to therapeutic regimen， with 40 cases in each group. Linezolid group received Linezolid injection 600 mg， ivgtt， bid； teicoplanin group received Teicoplanin injection 0.4 g， ivgtt， bid； vancomycin group received Vancomycin injection 1 000 mg， bid， ivgtt. 3 groups received 2 weeks of treatment. Clinical efficacy and bacterial clearance effective rate of 3 groups were observed as well as serum levels of inflammatory factors before and after treatment. ADR of 3 groups were compared. RESULTS： The clinical effective rates of linezolid group， teicoplanin group and vancomycin group were 90.0％， 72.5％ and 67.5％； the effective bacterial clearance rates were 85.0％， 60.0％ and 57.5％， respectively. The clinical effective rate and the effective bacterial clearance rate in linezolid group were significantly higher than those in teicoplanin group and vancomycin group， with statistical significance （P＜0.05）. There was no statistical significance in above indexes between teicoplanin group and vancomycin group （P＞0.05）. There was no statistical significance serum inflammatory factors among 3 groups before treatment （P＞0.05）. CRP and PCT of 3 groups decreased significantly after treatment， and those of linezolid group were lower than teicoplanin group and vancomycin group， with statistical significance （P＜0.05）. There was no statistical significance in serum inflammatory factors between teicoplanin group and vancomycin group before and after treatment （P＞0.05）. There was no statistical significance in the incidence of ADR among 3 groups （P＞0.05）. CONCLUSIONS： For hospital-acquired MRSA pneumonia， linezolid is better than teicoplanin and vancomycin in pneumonia control with good safety.